- Home
- COEP vs PMN Comparison
COEP vs PMN Comparison
Compare COEP & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COEP
- PMN
- Stock Information
- Founded
- COEP 2017
- PMN 2004
- Country
- COEP United States
- PMN Canada
- Employees
- COEP N/A
- PMN N/A
- Industry
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- PMN Pharmaceuticals and Biotechnology
- Sector
- COEP Health Care
- PMN Health Care
- Exchange
- COEP Nasdaq
- PMN Nasdaq
- Market Cap
- COEP 32.0M
- PMN 17.0M
- IPO Year
- COEP N/A
- PMN N/A
- Fundamental
- Price
- COEP $7.41
- PMN $0.49
- Analyst Decision
- COEP
- PMN Strong Buy
- Analyst Count
- COEP 0
- PMN 2
- Target Price
- COEP N/A
- PMN $4.50
- AVG Volume (30 Days)
- COEP 30.9K
- PMN 39.5K
- Earning Date
- COEP 08-15-2025
- PMN 08-07-2025
- Dividend Yield
- COEP N/A
- PMN N/A
- EPS Growth
- COEP N/A
- PMN N/A
- EPS
- COEP N/A
- PMN N/A
- Revenue
- COEP $62,874.00
- PMN N/A
- Revenue This Year
- COEP N/A
- PMN N/A
- Revenue Next Year
- COEP N/A
- PMN N/A
- P/E Ratio
- COEP N/A
- PMN N/A
- Revenue Growth
- COEP N/A
- PMN N/A
- 52 Week Low
- COEP $2.31
- PMN $0.47
- 52 Week High
- COEP $13.70
- PMN $2.37
- Technical
- Relative Strength Index (RSI)
- COEP 39.49
- PMN 45.60
- Support Level
- COEP $7.21
- PMN $0.48
- Resistance Level
- COEP $8.86
- PMN $0.53
- Average True Range (ATR)
- COEP 0.60
- PMN 0.02
- MACD
- COEP -0.02
- PMN 0.00
- Stochastic Oscillator
- COEP 34.55
- PMN 26.86
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.